Creo Medical’s H125 trading update delivered early results from the company’s streamlined focus on its core technology franchise and cost optimisation, following a strategic review in H224. Core technology revenues grew c 40% y-o-y to £2.2m (£1.6m in H124), driven by growing traction from Speedboat
